Suppliers / Allergan Sales

Allergan Sales

United States 5 duplicate records merged Updated 9 July 2026

Allergan Sales is an API and finished-dose manufacturer based in United States. It appears in 45 regulatory filings across 7 regulators, without an active US DMF or CEP on file. Its filings concentrate with DIGEMAPS (DO), EDE (AE) and ARCSA (EC). Its GMP standing is certified by MFDS (Korea), US FDA and ANVISA (Brazil). Its most recent recorded inspection, by US FDA, closed on 3 September 2024 as NAI.

0
active US DMFs
0
valid CEPs
6
registered plants 4 with an FDA FEI number
45
filings across 7 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
4 of 4 confirmed
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 3 September 2024 NAI US FDA
  • 28 July 2023 NAI US FDA
  • 24 March 2022 NAI US FDA
  • 24 June 2021 VAI US FDA
  • 29 July 2019 VAI US FDA
  • 27 February 2019 VAI US FDA
  • 1 February 2017 NAI US FDA
  • 28 October 2016 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Texas 76712, United Arab Emirates Not on file
WACO, United States Not on file
Irvine, United States 2011068
Campbell, United States 3000720089
Cincinnati, United States 1523957
Waco, United States 1643525

What they file, and where

Molecule Regulators Docs
Ketorolac SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
DIGEMAPS (DO) 24 None
EDE (AE) 12 None
ARCSA (EC) 4 None
NPRA (MY) 2 None
DPM (TN) 1 None
MINSA (CR) 1 None
MFDS (Korea) None 2
US FDA None 2
ANVISA (Brazil) None 1

Comparing suppliers?

Choose your molecules and target markets. Allergan Sales comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 3 September 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates